CoChat
Sign Up
Cited by 45Neuroendocrine Tumor Research AdvancesMedical Imaging Techniques and ApplicationsPeptidase Inhibition and Analysis

Contemporary nuclear medicine imaging of neuroendocrine tumours

Wong, K.K., Waterfield, R.T., Marzola, M.C., Scarsbrook, A.F., Chowdhury, F.U., Gross, M.D., Rubello, D.·2012·Clinical Radiology
DOI 10.1016/j.crad.2012.03.019
Open this paper in CoChat — free account

Abstract

Neuroendocrine tumours (NETs) are rare, heterogeneous, and often hormonally active neoplasms. Nuclear medicine (NM) imaging using single photon- and positron-emitting radiopharmaceuticals allows sensitive and highly specific molecular imaging of NETs, complementary to anatomy-based techniques, such as computed tomography (CT) and magnetic resonance imaging (MRI). Somatostatin-receptor scintigraphy is a whole-body imaging technique widely used for diagnosis, staging and restaging of NETs. The increasing availability of hybrid single-photon emission CT (SPECT)/CT cameras now offers superior accuracy for localization and functional characterization of NETs compared to traditional planar and SPECT imaging. The potential role of positron-emission tomography (PET) tracers in the functional imaging of NETs is also being increasingly recognized. In addition to 2-[(18)F]-fluoro-2-deoxy-d-glucose (FDG), newer positron-emitting radiopharmaceuticals such as (18)F-dihydroxyphenylalanine (DOPA) and (68)Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) peptides, show promise for the future. This article will summarize the role of current and emerging radiopharmaceuticals in NM imaging of this rare but important group of tumours.

Integrity signals

Registry

Crossref · 10.1016/j.crad.2012.03.019

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Other PET tracers including 18F-fluorodopamine, 18F-DOPA, and 11C-hydroxyephedrine have been used to evaluate tumors arising from the neural crest.

    “Other PET tracers including dopamine analogs such as 18F-fluorodopamine and 18F-fluorodihydroxyphenylalanine (DOPA) which image norepinephrine (noradrenaline) and amino acid transporter expression, along with 11C-hydroxyephedrine, a catecholamine analog, have been used to evaluate tumors arising from the neural crest (373) (Fig. 13).”

    From Adrenal incidentaloma (2020) · cites this paper as [373]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

  • Adrenal incidentaloma

    Sherlock, M., Scarsbrook, A., Abbas, A., Fraser, S., Limumpornpetch, P., Dineen, R., & Stewart, P. M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa008 · Cited by 347 · see citing works

    “Other PET tracers including dopamine analogs such as (18)F-fluorodopamine and (18)F-fluorodihydroxyphenylalanine (DOPA) which image norepinephrine (noradrenaline) and amino acid transporter expression, along with (11)C-hydroxyephedrine, a catecholamine analog, have been used to evaluate tumors arising from the neural…”
    BackgroundSelf-citation

Related

Authors
Wong, K. K., Waterfield, R. T., Marzola, M. C., Scarsbrook, A. F., Chowdhury, F. U., Gross, M. D., & Rubello, D.
Affiliations
  • VA Ann Arbor Healthcare System (US)
  • Ospedale Santa Maria della Misericordia di Rovigo (IT)
  • St James's University Hospital (GB)
ORCID
Venue
Clinical Radiology
Publisher
Elsevier BV
Published
2012-11
Volume
67
Issue
11
Pages
1035-1050
ISSN
0009-9260 (ISSN-L)
DOI
10.1016/j.crad.2012.03.019
OpenAlex
W2070449405
Cited by
45
References
112
Citations by year
2026: 1 · 2023: 2 · 2020: 4 · 2019: 3 · 2018: 1 · 2017: 4 · 2016: 6 · 2015: 5 · 2014: 6 · 2013: 12 · 2012: 1
FWCI
0.96
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Clinical Radiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Oncology › Peptidase Inhibition and Analysis
Keywords
neuroendocrine tumors, scintigraphy, somatostatin receptor scintigraphy, SPECT/CT, positron emission tomography, FDG-PET, 18F-DOPA, radiopharmaceuticals, functional imaging
MeSH terms
Chromaffin System, Dihydroxyphenylalanine, Gallium Radioisotopes, Humans, Tomography, Emission-Computed, Single-Photon, Neuroendocrine Tumors, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review